Results 31 to 40 of about 3,108,169 (356)

The DEAD/DEAH box helicase, DDX11, is essential for the survival of advanced melanomas

Molecular Cancer, 2012
Background Despite continuous efforts to identify genes that are pivotal regulators of advanced melanoma and closely related to it, to determine which of these genes have to be blocked in their function to keep this highly aggressive disease in check, it
Bhattacharya Chitralekha, Wang Xiaolei, Becker Dorothea   +2 more
doaj   +1 more source

Outcome and treatment-related adverse events of combined immune checkpoint inhibition with flipped dosing in a real-world cohort of 79 patients with metastasized melanoma

Frontiers in Oncology, 2023
IntroductionCombined immune checkpoint inhibition (ICI) with ipilimumab and nivolumab is a widely used treatment regimen for metastatic melanoma with non-resectable metastases.
Charlotte Nübel, Teresa Amaral, Ulrike Leiter, Lukas Flatz, Andrea Forschner   +4 more
doaj   +1 more source

Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma

JAMA Oncology, 2023
Key Points Question Is a habitual diet associated with tumor response to immune checkpoint blockade (ICB) in advanced melanoma? Findings In this cohort study of 91 patients with advanced melanoma in the UK and the Netherlands, higher adherence to the ...
L. Bolte, KarlaA Lee, J. Björk, E. Leeming, M. J. E. Campmans-Kuijpers, J. D. de Haan, A. V. Vila, Andrew Maltez-Thomas, N. Segata, R. Board, M. Harries, P. Lorigan, E. de Vries, P. Nathan, R. Fehrmann, V. Bataille, T. Spector, G. Hospers, R. Weersma   +18 more
semanticscholar   +1 more source

The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England [PDF]

, 2018
Background: Nivolumab was the first programmed death receptor 1 (PD-1) immune checkpoint inhibitor to demonstrate long-term survival benefit in a clinical trial setting for advanced melanoma patients.
Ellis, John, Hertel, Nadine, Johnson, Helen, Lee, Dawn, Meng, Yang, Morais, Edith, Philips, Zoe, Roskell, Neil, Walker, Andrew   +8 more
core   +1 more source

Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma.

Cancer Cell, 2023
Immune checkpoint inhibitors (ICIs), including CTLA-4- and PD-1-blocking antibodies, can have profound effects on tumor immune cell infiltration that have not been consistent in biopsy series reported to date. Here, we analyze seven molecular datasets of
Katie M. Campbell, Meelad Amouzgar, Shannon M. Pfeiffer, Tim Howes, Egmidio Medina, M. Travers, Gabriela Steiner, J. Weber, J. Wolchok, J. Larkin, F. Hodi, S. Boffo, Lisa Salvador, D. Tenney, Tracy Tang, Marshall A. Thompson, Christine N. Spencer, Daniel K. Wells, A. Ribas   +18 more
semanticscholar   +1 more source

Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France

Current Oncology, 2022
Nine drugs have been marketed for 10 years for the treatment of advanced melanoma (AM). With half of patients reaching a second line, the optimal sequence of treatments remains unclear.
Marguerite Kandel, Aurélie Bardet, Stéphane Dalle, Clara Allayous, Laurent Mortier, Bernard Guillot, Caroline Dutriaux, Marie-Thérèse Leccia, Sophie Dalac, Henri Montaudie, Philippe Saiag, Delphine Legoupil, Florence Brunet-Possenti, Jean-Philippe Arnault, Julie De Quatrebarbes, Marie Beylot-Barry, Eve Maubec, Thierry Lesimple, François Aubin, Jean-Jacques Grob, Florence Granel-Brocard, Pierre-Emmanuel Stoebner, Alain Dupuy, Brigitte Dreno, Stefan Michiels, Céleste Lebbe, Isabelle Borget   +26 more
doaj   +1 more source

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. [PDF]

, 2018
BackgroundMucosal melanoma is an aggressive melanoma with poor prognosis. We assessed efficacy of pembrolizumab in patients with advanced mucosal melanoma in KEYNOTE-001 (NCT01295827), -002 (NCT01704287), and -006 (NCT01866319).MethodsPatients received ...
Arance, Ana S, Brown, Ewan, Butler, Marcus, Daud, Adil, Ebbinghaus, Scot, Hamid, Omid, Hodi, F Stephen, Hoeller, Christoph, Ibrahim, Nageatte, Long, Jianmin, Mortier, Laurent, Ribas, Antoni, Robert, Caroline, Schachter, Jacob, Walpole, Euan   +14 more
core   +1 more source

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

Journal of Clinical Oncology, 2022
PURPOSE The combination of talimogene laherparepvec (T-VEC) and pembrolizumab previously demonstrated an acceptable safety profile and an encouraging complete response rate (CRR) in patients with advanced melanoma in a phase Ib study.
J. Chesney, A. Ribas, G. Long, J. Kirkwood, R. Dummer, I. Puzanov, C. Hoeller, T. Gajewski, R. Gutzmer, P. Rutkowski, L. Demidov, P. Arenberger, S. Shin, P. Ferrucci, A. Haydon, J. Hyngstrom, J. V. van Thienen, S. Haferkamp, J. Guilera, B. Rapoport, A. Vanderwalde, Scott J. Diede, James Anderson, S. Treichel, Edward Chan, S. Bhatta, J. Gansert, F. Hodi, H. Gogas   +28 more
semanticscholar   +1 more source

Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study

Frontiers in Immunology, 2022
Survival is generally poor for Chinese patients with advanced melanoma because of high rates of acral and mucosal melanoma and limited therapeutic options.
Lu Si, Xiaoshi Zhang, Yongqian Shu, Hongming Pan, Di Wu, Jiwei Liu, Lili Mao, Xuan Wang, Xizhi Wen, Yanhong Gu, Lingjun Zhu, Shijie Lan, Xin Cai, Scott J. Diede, Haiyan Dai, Cuizhen Niu, Jianfeng Li, Jun Guo   +17 more
doaj   +1 more source

Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients

Cancer, 2023
Immune checkpoint inhibitors (ICIs) have substantially improved overall survival in patients with advanced melanoma; however, the lack of biomarkers to monitor treatment response and relapse remains an important clinical challenge.
Z. Eroglu, S. Krinshpun, E. Kalashnikova, Sumedha Sudhaman, Turkan Ozturk Topcu, Matthew Nichols, Justin Martin, Katherine M Bui, C. Palsuledesai, M. Malhotra, P. Olshan, J. Markowitz, N. Khushalani, A. Tarhini, J. Messina, A. Aleshin   +15 more
semanticscholar   +1 more source